Alison J. Black, MB, ChB; Howard L. McLeod, PharmD; Hillary A. Capell, MB, ChB, MD, FRCP; Robert H. Powrie, BSc; Lloyd K. Matowe, MSc; Stuart C. Pritchard, MSc; Elaina S.R. Collie-Duguid, PhD; David M. Reid, MB, ChB, MD, FRCP
Substantial hematologic toxicity limits the use of azathioprine.
To evaluate 1) polymorphic inactivation of azathioprine by thiopurine methyltransferase and 2) clinical toxicity.
Prospective cohort study.
Two rheumatology units.
67 patients for whom azathioprine was prescribed as second-line therapy for rheumatic disease.
Polymerase chain reaction-based assays were used to detect mutations in thiopurine methyltransferase. The primary end point was discontinuation of azathioprine therapy because of toxicity.
Six of 67 patients (9%) were heterozygous for mutant thiopurine methyltransferase alleles. Five of the 6 patients discontinued therapy within 1 month of starting treatment because of low leukocyte counts. The sixth patient did not adhere to treatment. Patients with wild-type thiopurine methyltransferase alleles received therapy longer than did patients with mutant alleles (median duration of therapy, 39 weeks [range, 6 to 180 weeks] and 2 weeks [range, 2 to 4 weeks], respectively; P = 0.018).
Analysis of thiopurine methyltransferase genotype is a quick way to identify patients at risk for acute toxicity from azathioprine.
Black AJ, McLeod HL, Capell HA, et al. Thiopurine Methyltransferase Genotype Predicts Therapy-Limiting Severe Toxicity from Azathioprine. Ann Intern Med. 1998;129:716–718. doi: 10.7326/0003-4819-129-9-199811010-00007
Download citation file:
Published: Ann Intern Med. 1998;129(9):716-718.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use